Primex News International

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Atul Jain as MD and Shantanu Chakravartty as CEO Launches “Globiq” Travel Retail Brand in India and South Asia

    August 9, 2025

    Cupid Limited Strengthens IVD Test Kits Business with Certification Pipeline, Capacity Expansion, and Global Market Expansion

    August 9, 2025

    Zypp Electric and Gurugram Traffic Police Launch ‘Green Hai Toh Zypp Hai’ Campaign to Promote EV Adoption and Road Safety

    August 9, 2025
    Facebook Twitter Instagram
    Primex News International
    • Home
    Facebook Twitter Instagram
    Primex News International
    Home»Health»IPCA Laboratories Ltd launches Diulcus to address Diabetic Foot Ulcer (DFU) in India
    Health

    IPCA Laboratories Ltd launches Diulcus to address Diabetic Foot Ulcer (DFU) in India

    By August 17, 2024No Comments2 Mins Read
    Facebook Twitter Pinterest Telegram LinkedIn Tumblr WhatsApp Email
    Share
    Facebook Twitter LinkedIn Pinterest Telegram Email

    Mumbai (Maharashtra) [India], August 16: As per the ICMR-INDIAB (2023) study, 10 crore people in India suffer from diabetes, with an additional 13.6 crore people affected by pre-diabetes. This significant health concern positions India to become the diabetes capital of the world by 2030.

    In response to this serious healthcare challenge, IPCA Laboratories Ltd proudly announces the launch of Diulcus, a novel product aimed at addressing the challenges of Diabetic Foot Ulcer (DFU) in the Indian market. Diulcus, developed by NovaLead Pharma Pvt Ltd, a pioneer in drug repurposing, represents a significant advancement in the management of DFU. The product has received approval from the Central Drugs Standard Control Organization (CDSCO) and was partially funded by the Biotechnology Industry Research Assistance Council (BIRAC), a Government of India enterprise.

    The launch event was graced by esteemed personalities, including Sri. Premchand Godha, Sri AK Jain, Dr. Anil Pareek, Sri Sunil Ghai, and Sri. Supreet Deshpande.

    During phase 3 trials in India, Diulcus demonstrated remarkable efficacy, with a 60.3% ulcer closure rate within three months of treatment. Remarkably, patients continued to show an ulcer closure rate of 77.20% over six months, even after stopping treatment at three months. These results are among the best observed for any pharmaceutical preparation used in DFU treatment.

    Mr. Premchand Godha, Executive Chairman of IPCA Laboratories Ltd, expressed his enthusiasm about the launch, stating, “With over 15% of diabetic patients suffering from DFU at least once in their lifetime, DFU is the most prevalent complication caused by chronic diabetes. The approval of this patented repurposed drug is significant because DFU is the leading cause for lower limb amputations globally. We are delighted to partner with NovaLead Pharma Pvt Ltd through an IP licensing arrangement to bring Diulcus® for DFU patients in India. It demonstrates IPCA’s commitment towards the patients suffering from unmet medical need and its focus on the diabetes therapy.”

    Diulcus will be made available to the patients of DFU by Ipca Laboratories Ltd. (Ipca) through an exclusive IP licensing arrangement with NovaLead for Indian starting August 2024.

    Disclaimer: The article is for general information purposes only and should not be construed as professional medical advice. Always consult your doctor before taking any step.

    If you have any objection to this press release content, kindly contact pr.error.rectification@gmail.com to notify us. We will respond and rectify the situation in the next 24 hours.

    Health
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Related Posts

    Bone & Joint Day 2025: Expert Advice on Prevention, Early Care & Mobility Health

    August 4, 2025

    Concept Medical Enrolls First Patient in MAGICAL-SV IDE Trial, Expands Coronary Program Globally

    August 4, 2025

    Geomedi Medical University Stands Out For Its High-Quality Education, Excellent FMGE Passing Rate, And Advanced Training Facilities Available On Campus

    August 2, 2025

    India’s First AR Skull Base Cadaver Course Held at Apollo ENT Meet

    August 2, 2025

    Rasayanam Expands Its Wellness Range with Three New Powerhouse Products: Shilajit Gold, Magnesium Glycinate, and Shatavari

    July 29, 2025

    Homeopathy Gave Me a New Life: Lalaram Yadav’s Triumph Over Aplastic Anemia

    July 29, 2025

    Comments are closed.

    Top Reviews
    Editors Picks

    Atul Jain as MD and Shantanu Chakravartty as CEO Launches “Globiq” Travel Retail Brand in India and South Asia

    August 9, 2025

    Cupid Limited Strengthens IVD Test Kits Business with Certification Pipeline, Capacity Expansion, and Global Market Expansion

    August 9, 2025

    Zypp Electric and Gurugram Traffic Police Launch ‘Green Hai Toh Zypp Hai’ Campaign to Promote EV Adoption and Road Safety

    August 9, 2025

    Cupid Limited Starts FY26 with Solid Growth, Q1 Revenue Rises 47% & Net Profit Grows 82%

    August 9, 2025
    About Us
    About Us
    Our Picks

    Atul Jain as MD and Shantanu Chakravartty as CEO Launches “Globiq” Travel Retail Brand in India and South Asia

    August 9, 2025

    Cupid Limited Strengthens IVD Test Kits Business with Certification Pipeline, Capacity Expansion, and Global Market Expansion

    August 9, 2025

    Zypp Electric and Gurugram Traffic Police Launch ‘Green Hai Toh Zypp Hai’ Campaign to Promote EV Adoption and Road Safety

    August 9, 2025
    Top Reviews
    © 2025 Primex News International. Designed by Primex Media Services.
    • Home

    Type above and press Enter to search. Press Esc to cancel.